Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar 25;8(3):410.
doi: 10.3390/jcm8030410.

Evolution of Guidelines for Testosterone Replacement Therapy

Affiliations
Editorial

Evolution of Guidelines for Testosterone Replacement Therapy

Hyun Jun Park et al. J Clin Med. .

Abstract

Testosterone is an essential hormone required for the developmental growth and maintenance of the male phenotype during the whole life. With the increasing male life expectancy worldwide and development of adequate testosterone preparations, the prescription of testosterone has increased tremendously. Testosterone replacement should be based on low serum testosterone and related clinical symptoms. In the last two decades, with the accumulation of data, official recommendations have evolved in terms of definition, diagnosis, treatment, and follow-up. In practice, it is better for physicians to follow the Institutional Official Recommendations or Clinical Practice Guideline for an adequate diagnosis and treatment of testosterone deficiency. Currently, four official recommendations are available for diagnosis and treatment of patients with testosterone deficiency. The inconsistencies in the guidelines merely create confusion among the physicians instead of providing clear information. Furthermore, there is no definite method to assess serum testosterone and clinical symptoms. In the era of active testosterone replacement therapy (TRT), physicians' practice patterns should be consistent with the clinical practice guidelines to avoid the misuse of testosterone. In this review, the author introduces the evolution of clinical guidelines to provide a comprehensive understanding of the differences and controversies with respect to TRT.

Keywords: androgens; hypogonadism; men’s health; testosterone.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Baillargeon J., Urban R.J., Kuo Y.F., Holmes H.M., Raji M.A., Morgentaler A., Howrey B.T., Lin Y.L., Ottenbacher K.J. Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001–2010. Public Health Rep. 2015;130:143–152. doi: 10.1177/003335491513000207. - DOI - PMC - PubMed
    1. Baillargeon J., Urban R.J., Ottenbacher K.J., Pierson K.S., Goodwin J.S. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern. Med. 2013;173:1465–1466. doi: 10.1001/jamainternmed.2013.6895. - DOI - PMC - PubMed
    1. Layton J.B., Li D., Meier C.R., Sharpless J.L., Sturmer T., Jick S.S., Brookhart M.A. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J. Clin. Endocrinol. Metab. 2014;99:835–842. doi: 10.1210/jc.2013-3570. - DOI - PMC - PubMed
    1. Vigen R., O’Donnell C.I., Baron A.E., Grunwald G.K., Maddox T.M., Bradley S.M., Barqawi A., Woning G., Wierman M.E., Plomondon M.E., et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–1836. doi: 10.1001/jama.2013.280386. - DOI - PubMed
    1. Finkle W.D., Greenland S., Ridgeway G.K., Adams J.L., Frasco M.A., Cook M.B., Fraumeni J.F., Jr., Hoover R.N. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE. 2014;9:e85805. doi: 10.1371/journal.pone.0085805. - DOI - PMC - PubMed

Publication types

LinkOut - more resources